Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Recent Highlights: End-of-Phase 2 FDA interaction sets guidance to enable initiation of NGX-1998 Phase 3 studies Presented NGX-1998 Phase 2 trial data at World Congress; showed clear dose...
-
SAN MATEO, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
-
NGX-1998 Phase 2 Study Data Presented at World Congress on Pain Multiple Posters on Qutenza® Presented by Partner Astellas SAN MATEO, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- NeurogesX,...
-
SAN MATEO, Calif., Aug. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
-
SAN MATEO, Calif., Aug. 7, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
-
Q2 2012 and Recent Highlights: Business development process proceeding for NGX-1998 and Qutenza End-of-Phase 2 meeting package submitted and accepted by FDA Astellas enrolled first...
-
SAN MATEO, Calif., Aug. 2, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
-
SAN MATEO, Calif., July 27, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
-
Head-to-Head Study Will Compare Qutenza and Pregabalin in the Treatment of Peripheral Neuropathic Pain ELEVATE Study First to Compare Efficacy, Tolerability and Impact on Quality of Life Versus...
-
SAN MATEO, Calif., July 16, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...